Literature DB >> 24766623

Polymerase chain reaction evaluation of infectious multifocal serpiginoid choroiditis.

Neha Mohan1, Praveen Kumar Balne, Krushna Gopal Panda, Savitri Sharma, Soumyava Basu.   

Abstract

PURPOSE: To study infectious agents associated with multifocal serpiginoid choroiditis (MSC) based on polymerase chain reaction (PCR) evaluation and specific anti-microbial therapy.
METHODS: Retrospective review of medical records.
RESULTS: Thirteen patients with MSC were evaluated with PCR for the following organisms: Mycobacterium tuberculosis (MTB), herpes simplex virus 1 (HSV 1), varicella zoster virus (VZV), and cytomegalovirus (CMV). Nine (69.2%) were PCR positive for one or more organisms. Seven (53.8%) were positive for MTB, 3 (23.1%) for CMV (1 positive for both MTB and CMV), and 1 (7.6%) for both HSV 1 and MTB. All 13 patients received anti-TB therapy and corticosteroids. Nine patients completed 6 months follow-up; 6 resolved completely, 2 continued to have active lesions, while 1 CMV PCR-positive patient required additional valgancyclovir therapy.
CONCLUSIONS: TB is the most important etiology for MSC in endemic countries. The role of herpes viruses in MSC remains unclear and needs further investigation.

Entities:  

Keywords:  Chain reaction; infectious; multifocal serpiginoid choroiditis; polymerase; tuberculosis; viral

Mesh:

Substances:

Year:  2014        PMID: 24766623     DOI: 10.3109/09273948.2014.907433

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Real-time and nested polymerase chain reaction in the diagnosis of multifocal serpiginoid choroiditis caused by Mycobacterium tuberculosis - a case report.

Authors:  Sachin B Shetty; Jyotirmay Biswas; Sowmiya Murali
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-11-18

2.  Quantitative polymerase chain reaction analysis of serpiginous choroiditis with biopsy-proven testicular tuberculosis.

Authors:  Abhinav Dhami; Ranju Kharel Sitaula; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2018-02       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.